Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MERCK SERONO ANNOUNCES COLLABORATION WITH BRISTOL-MYERS (ENG)


(The following press release from Merck KGaA was received by e-mail. It was not confirmed by the sender.)

News Release

Your Contact Phyllis Carter Phone +49 6151 72-7144

Merck Serono Announces Collaboration With Bristol-Myers Squibb for Glucophage in China for Treatment of Type 2 Diabetes

• Companies focused on expanding access to Glucophage® for patients with Type 2 diabetes in China • Type 2 Diabetes is a growing public health concern in China, with over 90 million people affected

Darmstadt, Germany, March 19, 2013 – Merck Serono, a division of Merck in Darmstadt, Germany, today announced a collaboration for promotion of the type 2 diabetes drug Glucophage® (metformin hydrochloride) under different formulations in China. Under terms of the agreement, Merck Serono and Bristol-Myers Squibb will co-promote Glucophage in China through a profit-sharing arrangement. Glucophage has been marketed by Bristol-Myers Squibb-SASS in China since 1999. The two companies will utilize their existing resources and complementary strengths, with Bristol-Myers Squibb-SASS continuing to manufacture Glucophage’s IR® (immediate release) formulation. The collaboration will seek to expand the geographic distribution of Glucophage as well as provide diabetes-related health and medical information including education for health professionals. In addition, the co-promotion will significantly increase outreach to hospitals. Other terms of the agreement were not disclosed.

The complete news release can be downloaded at the following link: http://news.merck.de/N/0/D836A69218EED590C1257B32006AB46C/$File/Chi-Glu-MS.pdf

News releases from Merck KGaA, Darmstadt, Germany, are available at this address: www.merckgroup.com/media or for residents in the USA and Canada at www.emdgroup.com/media

In case you are a resident of the USA or Canada please go to http://www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email.

Merck KGaA ,Darmstadt, Germany External Communications E-mail: Media.Relations@merck.de Hotline: +49 (0) 6151/72-5000

This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith.

Click http://disclaimer.merck.de to access the German, French, Spanish and Portuguese versions of this disclaimer.

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement